PCM Trials, a Denver-based leader in decentralized clinical trials, has acquired EmVenio Research to enhance patient-centricity. This collaboration strengthens their ability to recruit diverse populations and address underrepresentation in clinical research. By leveraging EmVenio’s mobile site network and PCM Trials’ innovative approach, the partnership aims to minimize barriers, improve retention rates, and pioneer inclusive global clinical trial facilitation.
PCM Trials, headquartered in Denver and renowned as the foremost independent provider of mobile research nurse visits for decentralized clinical trials (DCTs), has proudly disclosed its acquisition of EmVenio Research, headquartered in Durham, North Carolina. This strategic move, effective immediately, consolidates PCM Trials’ position and augments its capability alongside EmVenio, a leader in community-based clinical trial sites supported by mobile research units. The union amplifies their capacity to recruit and retain diverse participant pools essential for regulatory endorsement. Central to sponsor objectives, the collaboration enhances the delivery of pivotal study data by leveraging EmVenio’s extensive site network, which prioritizes underserved patient demographics and previously inaccessible regions.
Greg Austin, President of PCM Trials, emphasized the significance of the EmVenio acquisition within their overarching mission to foster inclusivity across clinical research endeavors. He highlighted the pioneering utilization of Certified Mobile Research Nurses, a methodology already proven to elevate patient engagement and diversity while expediting study timelines. With EmVenio’s network integration, PCM Trials now possesses unparalleled flexibility in catering to prospective participants’ needs, thereby democratizing access to community-based clinical trials.
Addressing long-standing concerns raised by regulatory bodies such as the FDA regarding minority representation in clinical trials, the amalgamation of PCM Trials and EmVenio introduces a dynamic recruitment and visitation framework tailored to underrepresented communities. Statistical data underscore the gravity of this issue, with significant disparities observed in minority participation rates compared to their demographic presence. By capitalizing on EmVenio’s track record of activating mobile sites across a diverse range of therapeutic studies, coupled with an exceptional retention rate exceeding industry standards, the collaborative venture sets a new benchmark in patient-centric research facilitation.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Thad Wolfram, President of EmVenio, echoed sentiments of enthusiasm, affirming the combined entity’s commitment to pioneering global patient visitation solutions that transcend traditional site-centric models. The merged expertise aligns with a shared ethos of minimizing participation barriers while enhancing participant experiences, thereby elevating the accessibility and inclusivity of clinical research initiatives.
Greg Austin reiterated the pragmatic rationale underpinning their approach, emphasizing the pivotal role of convenience in driving recruitment and retention metrics. By mitigating logistical hurdles often faced by patients, particularly those residing in remote or underserved locales, PCM Trials and EmVenio empower individuals to engage with research initiatives within the familiarity of their homes or communities. This strategic ethos resonates with PCM Trials’ recent acquisition of Clinical Trial Service (CTS), further solidifying its global footprint and expertise in facilitating clinical trials on an unprecedented scale.
“With these acquisitions, we are now the largest and most experienced clinical research local access provider on a global scale,” affirmed Austin, signaling PCM Trials’ ascendancy as a pivotal player in shaping the landscape of patient-centric clinical research facilitation.